Physician profile
Antonio Cusi
NPI 1487643151
$147,189.07
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $14K · 2021: $17K · 2022: $64K · 2023: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Travel and Lodging: $4,737 · Food and Beverage: $599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,300.00 |
| Travel and Lodging | $4,737.42 |
| Food and Beverage | $599.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $98,992.86 | 2021-2023 | Vraylar |
| Allergan, INC. | $15,284.72 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $10,783.96 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $9,091.88 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $4,843.38 | 2019-2021 | |
| Validus Pharmaceuticals LLC | $1,835.20 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,244.92 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $652.05 | 2019-2021 | |
| Lundbeck LLC | $527.66 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $419.32 | 2019-2023 | Ingrezza |
| Eisai INC. | $357.56 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $343.86 | 2019-2021 | |
| Alkermes, INC. | $321.60 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $316.29 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $254.70 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $223.06 | 2019-2021 | |
| Ucb, INC. | $197.94 | 2019-2020 | |
| Tris Pharma INC | $193.84 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $192.72 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $175.14 | 2019-2020 | |
| Bausch Health US, LLC | $132.95 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $112.98 | 2021 | |
| Neos Therapeutics, Lp | $107.06 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $100.35 | 2021 | |
| Merck Sharp & Dohme LLC | $97.39 | 2019-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $87.50 | 2019 | |
| Shire North American Group INC | $84.59 | 2019 | |
| Indivior INC. | $69.62 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $60.97 | 2019-2020 | |
| Almatica Pharma LLC | $55.46 | 2021-2022 | |
| Corium, LLC | $15.82 | 2021 | |
| Pernix Therapeutics Holdings, INC. | $11.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Cusi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.